Carmelo Rizzari

Summary

Affiliation: Ospedale San Gerardo
Country: Italy

Publications

  1. ncbi request reprint Outcome of very late relapse in children with acute lymphoblastic leukemia
    Carmelo Rizzari
    Pediatric Department of Monza, Italy
    Haematologica 89:427-34. 2004
  2. ncbi request reprint A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia
    Carmelo Rizzari
    Department of Pediatric Hematology Oncology, University of Milano Bicocca, S Gerardo Hospital, Monza, Italy
    Haematologica 91:24-31. 2006
  3. ncbi request reprint Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study
    Valentino Conter
    Department of Pediatrics, Ospedale S Gerardo, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
    Blood 123:1470-8. 2014
  4. ncbi request reprint Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies
    Andrea Biondi
    Centro Ricerche Leucemie Infantili M Tettamanti, Clinica Pediatrica Università Milano Bicocca, Monza, Italy
    Haematologica 91:534-7. 2006
  5. doi request reprint Optimizing asparaginase therapy for acute lymphoblastic leukemia
    Carmelo Rizzari
    Department of Pediatrics, San Gerardo Hospital, University of Milano Bicocca, Monza, Italy
    Curr Opin Oncol 25:S1-9. 2013
  6. doi request reprint Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease
    Carmelo Rizzari
    Department of Pediatrics, S Gerardo Hospital, Via Pergolesi 33, Monza, Italy
    Expert Rev Anticancer Ther 11:1391-401. 2011
  7. ncbi request reprint FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia
    Paolo Arrigoni
    Centro Ricerca M Tettamanti, Clinica Pediatrica Università di Milano Bicocca, Monza, Italy
    Br J Haematol 120:89-92. 2003
  8. doi request reprint A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1
    Paola Cianci
    Pediatric Genetic Unit, Pediatric Department at Monza Brianza per il Bambino e la sua Mamma MBBM Foundation, S Gerardo Hospital, Monza, Italy
    Am J Med Genet A 161:1401-4. 2013
  9. doi request reprint Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy
    Maurizio Arico
    Pediatric Hematology Oncology, Ospedale dei Bambini G Di Cristina, Palermo, Italy
    J Clin Oncol 26:283-9. 2008
  10. ncbi request reprint Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia
    Andrea Pession
    Associazione Italiana di Ematologia Oncologia Pediatrica AIEOP, University of Bologna, Bologna, Italy
    J Clin Oncol 23:7161-7. 2005

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Outcome of very late relapse in children with acute lymphoblastic leukemia
    Carmelo Rizzari
    Pediatric Department of Monza, Italy
    Haematologica 89:427-34. 2004
    ..The present study was aimed at investigating clinical features and treatment outcome of children with very late relapse, diagnosed and treated in Italy in the last 20 years...
  2. ncbi request reprint A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia
    Carmelo Rizzari
    Department of Pediatric Hematology Oncology, University of Milano Bicocca, S Gerardo Hospital, Monza, Italy
    Haematologica 91:24-31. 2006
    ..The main goal of the present study was to investigate the pharmacological effects of the administration of PEG-ASP given as a first-line product in children with ALL...
  3. ncbi request reprint Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study
    Valentino Conter
    Department of Pediatrics, Ospedale S Gerardo, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
    Blood 123:1470-8. 2014
    ..MRD-HR is associated with poor outcome despite intensive treatment and/or HSCT and may qualify for innovative therapies. The study was registered at www.clinicaltrials.gov as #NCT00613457. ..
  4. ncbi request reprint Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies
    Andrea Biondi
    Centro Ricerche Leucemie Infantili M Tettamanti, Clinica Pediatrica Università Milano Bicocca, Monza, Italy
    Haematologica 91:534-7. 2006
    ..The corresponding figures for patients treated in the ALL-91 high-risk protocol (reduced induction and nine blocks) were one of seven patients treated with chemotherapy only and none of two who were transplanted...
  5. doi request reprint Optimizing asparaginase therapy for acute lymphoblastic leukemia
    Carmelo Rizzari
    Department of Pediatrics, San Gerardo Hospital, University of Milano Bicocca, Monza, Italy
    Curr Opin Oncol 25:S1-9. 2013
    ..Based on the indications of different protocols, lack of cross-reactivity to the E. coli-derived products and taking into consideration regulatory factors and availability, crisantaspase may be considered a viable second-line therapy...
  6. doi request reprint Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease
    Carmelo Rizzari
    Department of Pediatrics, S Gerardo Hospital, Via Pergolesi 33, Monza, Italy
    Expert Rev Anticancer Ther 11:1391-401. 2011
    ..This article is focused on the current available information on MRD as a prognostic marker in childhood AML...
  7. ncbi request reprint FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia
    Paolo Arrigoni
    Centro Ricerca M Tettamanti, Clinica Pediatrica Università di Milano Bicocca, Monza, Italy
    Br J Haematol 120:89-92. 2003
    ..5%, P = 0.29). In APL patients, FLT3/ITD was strongly correlated to a higher white blood cell count at diagnosis and the M3 French-American-British subtype...
  8. doi request reprint A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1
    Paola Cianci
    Pediatric Genetic Unit, Pediatric Department at Monza Brianza per il Bambino e la sua Mamma MBBM Foundation, S Gerardo Hospital, Monza, Italy
    Am J Med Genet A 161:1401-4. 2013
    ....
  9. doi request reprint Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy
    Maurizio Arico
    Pediatric Hematology Oncology, Ospedale dei Bambini G Di Cristina, Palermo, Italy
    J Clin Oncol 26:283-9. 2008
    ..The prognostic value of DNA index was explored in this setting...
  10. ncbi request reprint Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia
    Andrea Pession
    Associazione Italiana di Ematologia Oncologia Pediatrica AIEOP, University of Bologna, Bologna, Italy
    J Clin Oncol 23:7161-7. 2005
    ....
  11. ncbi request reprint Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study
    Maurizio Arico
    Oncoematologia Pediatrica, Ospedale dei Bambini G Di Cristina, 90134 Palermo, Italy
    Haematologica 90:1186-91. 2005
    ..The aim of this study was to evaluate the efficacy of treatment reduction in a subset of children with ALL at minimal risk of failure...
  12. pmc Ancestry and pharmacogenetics of antileukemic drug toxicity
    Shinji Kishi
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 109:4151-7. 2007
    ..026). The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers. Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy...
  13. ncbi request reprint Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II
    Maurizio Arico
    Onco Ematologia Pediatrica, Ospedale dei Bambini G Di Cristina, Palermo, Italy
    Blood 100:420-6. 2002
    ..This modified therapy may lead to high cure rates for patients defined as at high risk for intrinsic resistance to corticosteroids only...